BioSpace News Archive

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 80,000 shares of its common stock to one employee outside Fusion’s 2020 Stock Option and Incentive Plan.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced its unaudited condensed consolidated interim financial statements for the first half of 2021.

R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at three upcoming investor conferences:

According to a new survey which aims to shed light on Coloradans understanding and knowledge of their fertility health, 75% of Coloradans admit to feeling “uninformed,” “clueless” or only “somewhat knowledgeable” about their fertility health.

Biocept, a leading provider of molecular diagnostic assays and services, announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees.

Poseida Therapeutics, Inc. today announced preliminary results from its Phase 1 clinical trial of P-PSMA-101, the Company’s solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC).

Cancer treatment can affect your ability to work and pay bills and as a result financial toxicity can become a significant concern and, in many cases, a reality for breast cancer patients.

Bayer, a global leader in women’s healthcare, announced today that it started the Phase III clinical development program OASIS,

PhotoPharmics announced today that it has appointed Karl Kieburtz, MD, MPH, as Chief Medical Officer (CMO).

Medvantx today announced the appointment of Nabil Badr as chief technology officer and Darlene Mitchell as chief compliance officer.